Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial

  1. Giné, E.
  2. de la Cruz, F.
  3. Jiménez Ubieto, A.
  4. López Jimenez, J.
  5. Martín García-Sancho, A.
  6. Terol, M.J.
  7. González Barca, E.
  8. Casanova, M.
  9. de la Fuente, A.
  10. Marín-Niebla, A.
  11. Muntañola, A.
  12. González-López, T.J.
  13. Aymerich, M.
  14. Setoain, X.
  15. Cortés-Romera, M.
  16. Rotger, A.
  17. Rodríguez, S.
  18. Medina Herrera, A.
  19. García Sanz, R.
  20. Nadeu, F.
  21. Beà, S.
  22. Campo, E.
  23. López-Guillermo, A.
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology

ISSN: 1527-7755

Year of publication: 2022

Volume: 40

Issue: 11

Pages: 1196-1205

Type: Article

DOI: 10.1200/JCO.21.02321 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals